BPG is committed to discovery and dissemination of knowledge
Featured Articles
3/27/2017 11:32:00 AM | Browse: 1075 | Download: 2071
Publication Name World Journal of Stem Cells
Manuscript ID 28727
Country Argentina
Received
2016-07-13 09:41
Peer-Review Started
2016-07-13 13:50
First Decision by Editorial Office Director
Return for Revision
2016-09-13 11:24
Revised
2016-10-12 00:04
Publication Fee Transferred
Editorial Processing by Scientific Editor
2016-12-12 10:44
Final Academic Decision by Editor-in-Chief
Publication Technical Verification by Editorial Office Director
2016-12-19 10:50
Articles in Press
2016-12-19 10:50
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-03-22 21:15
Publish the Manuscript Online
2017-03-26 20:06
ISSN 1948-0210 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Immunology
Manuscript Type Review
Article Title Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy
Manuscript Source Unsolicited Manuscript
All Author List Jorge Zorzopulos, Steven M Opal, Andrés Hernando-Insúa, Juan M Rodriguez, Fernanda Elías, Juan Fló, Ricardo A López, Norma A Chasseing, Victoria A Lux-Lantos, Maria F Coronel, Raul Franco, Alejandro D Montaner and David L Horn
Funding Agency and Grant Number
Corresponding Author Alejandro D Montaner, PhD, Instituto de Ciencia y Tecnologıa “Dr. Cesar Milstein”, Fundación Pablo Cassará, 2453 Saladillo Street, Ciudad Autonoma de Buenos Aires C1440FFX, Argentina. amontaner@fundacioncassara.org.ar
Key Words Immunohomeostasis; Immunoprotection; Immunoregeneration; Inflammation; Mesenchymal stem cells; IMT504
Core Tip Mesenchymal stem cell (MSC) transplant has been demonstrated to be an effective therapy in pre-clinical studies evaluating a vast diversity of inflam-ma-tory conditions. However, in clinical trials of transplanted MSCs, the expectations of great medical benefit have not yet been fulfilled. In this regard, IMT504, the prototype of a major class of immu-nomodulatory oligo-nucleo-tides, induces in vivo expan-sion of MSCs, resulting in a marked improvement in preclinical models of neuro-pathic pain, osteoporosis, diabetes and sepsis. IMT504 is easily manufactured and has an excellent preclinical safety record. Further clinical investigation is necessary to demonstrate the utility of IMT504 for resolution of inflammation and regeneration in a broad array of human diseases that are likely to benefit from an immunoprotective/immunoregenerative therapy.
Publish Date 2017-03-26 20:06
Citation Zorzopulos J, Opal SM, Hernando-Insúa A, Rodriguez JM, Elías F, Fló J, López RA, Chasseing NA, Lux-Lantos VA, Coronel MF, Franco R, Montaner AD, Horn DL. Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy. World J Stem Cells 2017; 9(3): 45-67
URL http://www.wjgnet.com/1948-0210/full/v9/i3/45.htm
DOI http://dx.doi.org/10.4252/wjsc.v9.i3.45
Full Article (PDF) WJSC-9-45.pdf
Full Article (Word) WJSC-9-45.doc